AmacaThera’s lung cancer applications recognized in QuickFire Challenge
by CM staff
The program was created with the goal of advancing technologies that benefit veterans.
TORONTO — AmacaThera, a clinical-stage biotechnology company developing injectable biomaterials for local, sustained delivery of oncology and pain therapeutics, has received grant funding from the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma.
The program, launched by Johnson & Johnson Innovation- JLABS with the Johnson & Johnson Office of Military and Veterans Affairs, was created with the goal of advancing technologies that benefit veterans.
With the QuickFire Challenge funding, AmacaThera will partner with another biotech company to collaborate on visualizing and sampling lung tumors. Through the partnership, the companies will explore AmacaThera’s hydrogel technology for the delivery of therapeutics to these hard-to-reach locations.
“We founded AmacaThera to revolutionize the range of treatment options available to patients using a range of therapeutic agents, such as small molecules, antibodies, proteins or peptides,” said Dr. Michael J. Cooke, CEO and co-founder, AmacaThera. “We’re honoured to be among the companies selected to participate in this program, and excited to form new collaborations.”
